A pilot dose finding study of pioglitazone in autistic children

Area of Science:

• Neuroscience
• Pharmacology
• Developmental Pediatrics

Background:

• Autism spectrum disorder (ASD) involves complex pathways, including immune system alterations.
• Pioglitazone is being investigated for its potential to modulate these pathways for ASD symptom treatment.

Purpose of the Study:

• To determine the maximum tolerated dose (MTD) and safety of pioglitazone in children with ASD.
• To explore preliminary efficacy signals and identify appropriate outcome measures for pioglitazone intervention.
• To assess pioglitazone's impact on core symptoms of autism spectrum disorder in pediatric participants.

Main Methods:

• A 16-week, single-arm, dose-finding pilot study was conducted in 25 children aged 5-12 years.
• Participants received pioglitazone at one of three daily doses: 0.25, 0.5, or 0.75 mg/kg, following a 2-week placebo run-in.
• Safety, tolerability, and efficacy were assessed using standardized behavioral scales and adverse event monitoring.

Main Results:

• The maximum tolerated dose was determined to be 0.75 mg/kg once daily, with no serious adverse events reported.
• Pioglitazone was generally well-tolerated, with mild neutropenia observed in three participants.
• Statistically significant improvements were noted in social withdrawal, repetitive behaviors, and externalizing behaviors, with 46% global responders.

Conclusions:

• Pioglitazone demonstrates a favorable safety profile and potential efficacy in improving core autism spectrum disorder symptoms.
• Early evidence suggests pioglitazone may positively impact social withdrawal, repetitive, and externalizing behaviors in children with ASD.
• Further randomized controlled trials are recommended to confirm these findings and establish pioglitazone's therapeutic role in ASD management.